Cargando…

Potential therapeutic role of budesonide to reduce COVID-19 severity

Detalles Bibliográficos
Autores principales:	Mohiuddin, Md, Kasahara, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585565/ https://www.ncbi.nlm.nih.gov/pubmed/34802976 http://dx.doi.org/10.1016/j.jiph.2021.11.003

Ejemplares similares

The emerging role of oxidative stress in complications of COVID-19 and potential therapeutic approach to diminish oxidative stress
por: Mohiuddin, Md, et al.
Publicado: (2021)

Exploration of potential risk factors for COVID-19 severity in patients participating in oncology clinical trials
por: Mohiuddin, Md, et al.
Publicado: (2021)

Cellular senescence is a potential severity factor for COVID-19: Suitable targets required to eliminate cellular senescence
por: Mohiuddin, Md, et al.
Publicado: (2021)

Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options
por: Mohiuddin, Md, et al.
Publicado: (2022)

Cancer metastasis may increase COVID-19 mortality: Suitable targets required to impede cancer metastasis
por: Mohiuddin, Md, et al.
Publicado: (2022)

The emerging role of cellular senescence in complications of COVID-19
por: Mohiuddin, Md, et al.
Publicado: (2021)

Potentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes
por: Dhurandhar, Nikhil V., et al.
Publicado: (2020)

Budesonide: A promising candidate therapeutic for early COVID-19
por: Patel, Shailesh Kumar, et al.
Publicado: (2021)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

High-dose budesonide for early COVID-19
por: Lipworth, Brian, et al.
Publicado: (2021)

High-dose budesonide for early COVID-19
por: Berezowski, Ivan, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: Choi, Jae Chol, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: San-Juan, Rafael, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19
por: Zeitlinger, Markus, et al.
Publicado: (2021)

Inhalatives Budesonid zur Therapie bei COVID-19
por: Kluge, S., et al.
Publicado: (2021)

Budesonide/formoterol combination for reducing cough in COVID-19 patients—A case of inflated expectations!
por: Kaur, Onkardeep, et al.
Publicado: (2023)

Efficacy of inhaled budesonide for the treatment of severe equine asthma
por: Lavoie, J. P., et al.
Publicado: (2018)

Role of nanomedicine in COVID-19 therapeutics
por: Sharma, Smriti
Publicado: (2022)

High-dose budesonide for early COVID-19 – Authors' reply
por: Hobbs, F D Richard, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19 – Authors' reply
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate
por: Liang, Yingjian, et al.
Publicado: (2021)

Vitamin D’s Role in Reducing Risk of SARS-CoV-2 and COVID-19 Incidence, Severity, and Death
por: Grant, William B.
Publicado: (2021)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Budesonid verhindert bei COVID-19 Übergang zu schwerem Verlauf
por: Reinhardt, Dietrich
Publicado: (2021)

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2020)

The Effectiveness of Budesonide Nasal Irrigation in Patients with Allergic Rhinitis
por: Ishak, Muhammad Nu’aim, et al.
Publicado: (2022)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
por: Arabi, Yaseen M., et al.
Publicado: (2020)

Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19
por: Agusti, Alvar, et al.
Publicado: (2021)

Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19?
por: Kareemi, Hashim, et al.
Publicado: (2021)

Budesonide and fluticasone and adrenal suppression
por: Fouda, Mona A, et al.
Publicado: (2012)

Eosinophilic cholangitis treatment with budesonide
por: De Roza, Marianne Anastasia, et al.
Publicado: (2017)

The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19
por: Saghafi, Nafiseh, et al.
Publicado: (2022)

Therapeutic effect of budesonide, montelukast and azithromycin on post-infectious bronchiolitis obliterans in children
por: Chen, Xia, et al.
Publicado: (2020)

Budesonide and Formoterol Reduce Early Innate Anti-Viral Immune Responses In Vitro
por: Davies, Janet M., et al.
Publicado: (2011)

Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice
por: Xian, Shiyun, et al.
Publicado: (2023)

P34.02 The Inhibitory Effect of Cisplatin, Paclitaxel, and Pemetrexed on the Growth of PC9GR Cells During the COVID-19 Pandemic
por: Mohiuddin, M., et al.
Publicado: (2021)

Continuous flow process for preparing budesonide
por: Phull, Manjinder Singh, et al.
Publicado: (2022)

Use of Budesonide in the Treatment of Microscopic Colitis
por: Tangri, Vikram, et al.
Publicado: (2010)

Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19
por: Gatta, Aditya Kiran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lqhs9mj0kngoaicfsr95ahbsgn